Members of the FDA AMDAC voted 16 Yes to 1 No in favor of Paxlovid’s overall benefit-risk assessment when used for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19, including hospitalization or death, according to multiple media reports on the advisory committee meeting.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PFE:
- Pfizer recalls Nurtec ODT on packaging issues, risk of poisoning
- Royalty Pharma raises FY23 adjusted cash receipt guidance to $2.85B-$2.95B
- Seagen downgraded to Equal Weight from Overweight at Morgan Stanley
- Pfizer’s deal in EU for Covid-19 vaccine meets some resistence, FT says
- JPMorgan biotech/pharma analysts to hold analyst/industry conference call
